ALK-Abelló A/S: Hypersensitivity trials
The registry lists 13 Hypersensitivity studies with ALK-Abelló A/S as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 3Phase 2 4Phase 3 5No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)CompletedNCT01469182Phase 3Results posted
- Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)CompletedNCT00978029Phase 2Results posted
- Efficacy of SLITone in House Dust Mite Allergic PatientsCompletedNCT00633919Phase 2/3Results posted
- Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and AsthmaCompletedNCT05476484
- N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in FranceCompletedNCT03746860
- A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy TabletCompletedNCT01675791Phase 2
- A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy TabletCompletedNCT01454544Phase 3
- Exposure Chamber Trial With Cat ImmunotherapyCompletedNCT00987909Phase 2
- Tolerability of ALK Tree TabletCompletedNCT00535639Phase 1
- Safety of ALK Ragweed TabletCompletedNCT00330083Phase 1
- Tolerability of Grazax-R in ChildrenCompletedNCT00298701Phase 1
- Assessment of Grazax® Treatment ComplianceCompletedNCT00293046Phase 3
- A Trial of the ALK Grass Tablet in Subjects With HayfeverCompletedNCT00227279Phase 3